Reading PVLA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PVLA free→Reading PVLA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PVLA free→NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak. Earnings quality cannot be assessed since the company was unprofitable over the past year. Management's recent track record has been steady, and it has made capital-friendly moves. Risk is elevated, and the sector backdrop is a headwind. Compared with sector peers, PVLA trades below typical levels. Peer multiples imply a price about 76% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk. This pattern suggests potential issues due to weak financials or fragile earnings quality. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $108.81. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $109 PVLA trades at 3× p/s, below its 9× p/s peer median. Our $442 fair value sits above the price; low confidence. Analysts: $210–$255. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 75% below a flat-multiple fair value, below our forecast of about -60%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 0.59x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
2 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-1.16 → $-1.16 (+0.0% / 30d). 2 raised, 6 cut, 12 covering analysts.
0 upgrades, 0 downgrades / 30d, 2 maintained. 100% of analysts rate Buy.
0 positive, 0 negative / 30d.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$279.
How much price usually moves either way.
On a bad day, this stock has moved -$689.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,111.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If the healthcare sector shows renewed growth, it may benefit Palvella. This could improve investor outlook.
Confirms:Healthcare sector revenue growth is speeding up. It is getting close to 10% or more.
Disproves:Healthcare sector revenue growth remains below 5%.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for PVLA yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 10, 2026, at the 2026 Annual Meeting of Stockholders (the “ Annual Meeting ”) of Palvella Therapeutics, Inc. (the “ Company ”), the Company’s stockholders approved the amendment (the “ Plan Amendment ”) to the Palvella Therapeutics, Inc. 2024 Equity Incentive Plan to increase the authorized shares issuable thereunder by 750,000 shares. The…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
$210.00 – $255.00 (median $220.00) · 5 analysts · as of 2026-05-12
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
PVLA Palvella Therapeutics, Inc. | Below typical Show detailsSector percentile: 23 of 100 | inexpensive | elevated |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 78 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Palvella aims to submit its NDA in the second half of 2026.
Newly stated in 2026-Q1. Palvella has not yet generated revenue, and the financials show a net income loss of $15.77 million in 2026-Q1. The NDA submission is a critical step toward potential revenue generation, but the trajectory is yet to be proven.
“NDA submission remains on track for the second half of 2026.”
Palvella is targeting its first FDA approval in the first half of 2027.
Newly stated in 2025-Q4. The company reported a net income loss of $12.71 million in 2025-Q4. While the Phase 3 results are promising, financials indicate ongoing losses, and the approval trajectory remains uncertain.
“Positive Phase 3 SELVA results put us on a path toward our first potential FDA approval in the first half of 2027.”
Palvella is focused on maintaining financial stability amid ongoing losses.
Newly stated in 2025-Q4. The company reported a net income loss of $12.71 million in 2025-Q4, with $55.9 million in cash and equivalents. Financial stability is a focus, but ongoing losses challenge this priority.
“The Company had approximately $55.9 million of cash, cash equivalents and marketable securities.”
Results of Operations and Financial Condition. On May 7, 2026, Palvella Therapeutics, Inc. (the “ Company ”) announced its financial results for the quarter ended March 31, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 1…
Results of Operations and Financial Condition. On March 31, 2026, Palvella Therapeutics, Inc. (the “ Company ”) announced its financial results for the year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Sectio…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 13, 2026 (the “ Appointment Date ”), the Board of Directors (the “ Board ”) of Palvella Therapeutics, Inc. (the “ Company ”) increased the size of the Board from six to seven members and, upon recommendation of the Nominating and Corporate Governance Committee, appointed John Doux, M.D., to serve as a Class III director, with an initial te…
Results of Operations and Financial Conditions. On February 24, 2026, Palvella Therapeutics, Inc. (the “ Company ”) announced that, as of December 31, 2025, the Company had approximately $55.9 million of cash, cash equivalents and marketable securities. The Company has not yet completed its financial close procedures. As a result, this amount may differ materially from the amount that will be reflected in the Company’s consolidated financial statements for the year ended December 31, 2025. Th…